Lerzeparib

Main purpose: Phase Ib (Phase I): To determine the recommended dosage of TQB3823 combined with bevacizumab for first-line maintenance treatment of patients with advanced ovarian cancer, fallopian tube cancer and primary peritoneal cancer in Phase III (Phase II); Phase III (Phase 2): This phase is designed to demonstrate the efficacy of TQB3823 in subjects with advanced ovarian, fallopian tube, and primary peritoneal cancer who have achieved complete response/partial response (CR/PR) after receiving first-line chemotherapy. Combined maintenance therapy with bevacizumab can significantly prolong progression-free survival (PFS) compared with bevacizumab injection alone;